When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100

Affiliations

• ¹ Department of Medicine, Division of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA.
• ² Department of Medicine, University of California San Francisco, San Francisco, California, USA [email protected].
• ³ Department of Medicine, University of California San Francisco, San Francisco, California, USA.